Like! I'll take .53...
INVESTMENT SUMMARY
Prescient has sharpened its focus on lead anti-cancer compound PTX-200 and plans to add a Phase Ib trial in acute myeloid leukaemia (AML) to the ongoing Phase I/II trials in breast and ovarian cancers. It has raised ~A$2m through a share purchase plan and placement, which will fund operations until 2017. We raise our valuation to A$49m (A$0.53/share), with the addition of the AML indication for PTX-200 more than offsetting the deferral of Phase 1b trials for PTX-100.
- Forums
- ASX - By Stock
- PTX
- Ann: Edison Investment Research Initiates Coverage
Ann: Edison Investment Research Initiates Coverage, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.6¢ |
Change
-0.004(8.00%) |
Mkt cap ! $37.04M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.5¢ | $27.48K | 578.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49107 | 4.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.7¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49107 | 0.046 |
2 | 49424 | 0.045 |
2 | 40000 | 0.044 |
4 | 301904 | 0.042 |
7 | 399000 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.047 | 100000 | 1 |
0.048 | 2664 | 1 |
0.050 | 177119 | 2 |
0.051 | 277227 | 2 |
0.052 | 10500 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |